Sunny Xie

Sunny Xie

Sunny Xie is the Vice President of Biometrics at Neogene Therapeutics. Before joining Neogene, Sunny served as VP of Biometrics at OncoSec Medical, where he supported the development of strategy and execution of the immune oncology therapy pIL-12 with electroporation in combination with a checkpoint inhibitor. Before OncoSec, Sunny served as the VP of Biometrics […]

June Seymour, CPA

June Seymour

June A. Seymour, CPA, is the Vice President of Finance at Neogene Therapeutics. Before joining Neogene, Ms. Seymour served as the Executive Director of Finance of Autolus Therapeutics PLC, where she oversaw the scaling of the company’s financial operations, SEC reporting, and Sarbanes Oxley compliance. She was an instrumental part of the teams that led […]

Catherine Lee, J.D.

Catherine Lee

Catherine Lee, J.D., is the General Counsel at Neogene Therapeutics.  She joined Neogene in 2022 with over 20 years of experience, advising public and privately held companies in biotechnology and other industries. Before joining Neogene, Catherine served as the Executive Vice President, General Counsel and Corporate Secretary of Metacrine, Inc., where she provided executive oversight […]

Raphaël Rousseau, M.D, Ph.D.

Raphaël Rousseau

Raphaël Rousseau, M.D., Ph.D. is the Chief Medical Officer of Neogene Therapeutics. Before joining Neogene, Dr. Rousseau served as Executive Vice President, Head of Product Development, and Chief Medical Officer at Gritstone bio, where he was responsible for the company’s global clinical development strategies and expansion of its neoantigen-based immunotherapies. Prior to Gritstone bio, Dr. […]

Sanne Weijzen Ph.D.

Sanne Weijzen, Ph.D.

Sanne Weijzen, Ph.D., is the Vice President, Corporate Strategy and EU Operations at Neogene Therapeutics. Dr. Weijzen has more than 20 years of combined academic and biotech industry experience. Before joining Neogene, she spent 4 years as a COO of Scenic Biotech, where she was responsible for finance, HR, IP and legal, while building the […]

Marisa Leonard

Marisa is the Head of Business Development at Neogene Therapeutics. Prior to joining Neogene, Marisa spent nearly five years at Kite, a Gilead Company, where she worked in Business Development. Marisa worked on the Gilead / Kite acquisition and was responsible for leading cell therapy transactions including partnerships, academic collaborations and outlicenses. Previously, Marisa was […]

Harish Mundre

Harish Mundre

Harish Mundre is the Vice President, Head of Information Technology at Neogene Therapeutics. In over 20 active years in the tech industry, Mr. Mundre has held several senior roles in notable companies such as Sun Microsystems and Amgen Inc. Before Neogene, he served as a co-founder and CTO of Polar Wave Technologies where he helped […]

Stephanie Heintz, M.P.H

Stephanie Heintz, M.P.H

Stephanie Heintz is the Executive Director, Head of Human Resources at Neogene Therapeutics. Before joining Neogene, Heintz served as Senior Director of Human Resources at AnaptysBio, where she was responsible for the development and execution of human resource strategy in support of the overall business plan, specifically in the areas of talent acquisition, organizational and […]

Han Lee, Ph.D.

Han Lee

Han Lee, Ph.D., MBA, is the Chief Financial Officer at Neogene Therapeutics. Before joining Neogene, Dr. Lee served as Chief Financial Officer of Arcellx where he oversaw the company’s financial operations, corporate financings, and was instrumental in its growth from pre-clinical to clinical. Previously, Dr. Lee worked in the Corporate Development and Ventures group at […]

David Lund, Ph.D.

David Lund

David Lund, Ph.D., is the Vice President, Intellectual Property at Neogene Therapeutics. Before coming to Neogene, Dr. Lund served most recently as Senior IP Counsel at Agenus, where his responsibilities included managing IP issues for Agenus’ affiliate AgenTus in addition to early stage and near-commercial antibody programs of Agenus. Prior to that, Dr. Lund was […]